Companies › Maia Biotechnology
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 6-Thio-2'-Deoxyguanosine Telomere targeting agent; preferentially incorporated into telomeres in telomerase-positiv | – | Phase 3 | Carcinoma, Non-Small -Cell Lung; Carcinoma, Non-Small-Cell Lung | Jul 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06908304 | 6-Thio-2'-Deoxyguanosine | Phase 3 | Carcinoma, Non-Small -Cell Lung | Oncology | Jul 2027 |
| NCT05208944 | 6-Thio-2'-Deoxyguanosine | Phase 2 | Carcinoma, Non-Small-Cell Lung | Oncology | Sep 2027 |
Cash of $0m on 2026-09-30
Press releases filed as 8-K in the last year:
No annotated target.
–
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals FutureGen Biopharmaceutical (Beijing) Epizyme CanariaBio pharmaand
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.